内容摘要：Take his love of the lanes outside with a fun game of backyard bowling. This DIY kid-size version is perfect for Dad and his little ones to play together.

Take his love of the lanes outside with a fun game of backyard bowling. This DIY kid-size version is perfect for Dad and his little ones to play together.

and hearing loss. This makes them risky for long-term use, especially in children or those already battling chronic illness.Now, an international team of scientists has discovered that another drug—mefloquine—could make aminoglycosides much more effective, even at lower doses. Originally used to fight malaria, mefloquine has now been shown to help ribosomes override faulty stop codons more efficiently.

The study, published in, was led by Dr. Albert Guskov at the. Using X-ray crystallography and cryogenic electron microscopy, his team captured detailed images of how mefloquine and aminoglycosides interact with the ribosome. These tools allowed the researchers to see where the drugs bind and how they change the ribosome’s behavior.

What they found was unexpected. Mefloquine binds near a part of the ribosome known as bridge B7b/c. This area is crucial for the ribosome’s subunits to rotate and function properly during protein production. When mefloquine binds here, it alters the dynamics of these movements. This shift makes it easier for aminoglycosides to encourage the ribosome to read through the incorrect stop codon and continue building the“It was exciting to discover something completely unexpected,” said Dr. Guskov. “A new mechanism that explains how drugs can help override a faulty stop signal. A very thrilling and motivating discovery.”

One of the diseases that could benefit most from this finding is Duchenne muscular dystrophy, or DMD. This condition affects mostly boys and causes progressive muscle weakening, often leading to early death. About 10% to 15% of DMD cases are due to nonsense mutations.

Right now, patients with this form ofDoctors have only gradually understood which gene variants are dangerous in which patients, and how to deal with them, said Alan Venook, a colorectal and liver cancer specialist at the University of California-San Francisco.

By the time Zembruski-Ruple’s doctors told her she had the deficiency, she had been on the drug for eight days, said Khavkine, who watched over his partner with her sister throughout the seven-week ordeal.Khavkine said he “would have asked for the test” if he had known about it, but added “nobody told us about the possibility of this deficiency.” Zembruski-Ruple’s sister also said she wasn’t warned about the fatal risks of the chemo, or told about the test.

“They never said why they didn’t test her,” Zembruski said. “If the test existed, they should have said there is a test. If they said, ‘Insurance won’t cover it,’ I would have said, ‘Here’s my credit card.’ We should have known about it.”Despite growing awareness of the deficiency, and an advocacy group made up of grieving friends and relatives